A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 79 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 20 in phase 3, and was the 21st registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 695 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 50th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2017, is one of 121 in phase 3, and was the 224th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.
Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (\<300 or ≥300 cells/μL).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter.
Key Inclusion Criteria:
Fulfilment of at least 1 of the following conditions over the 7 days prior to randomization:
Exclusion Criteria:
Known history of any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Biological: Benralizumab
Placebo administered subcutaneously
Biological: Placebo
Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
Placebo subcutaneously on study week 0 until study week 40 inclusive.
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL
Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Change from baseline at week 48 in total rescue medication use (number of puffs/day)
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Change from baseline at week 48 in morning PEF
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Change from baseline at week 48 in evening PEF
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.
Time frame: From randomization through Study Week 48
Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Time to first asthma exacerbation over 48-week treatment period
Time frame: From randomization through Study Week 48
Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Number and percentage of patients with at least one exacerbation over 48-week treatment period
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.
Time frame: From randomization through Study Week 48
Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period
Time frame: From randomization through Study Week 48
Number and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Asthma specific health care resource utilization over 48-week treatment period.
Time frame: From randomization through Study Week 48
The Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration
PK trough concentrations at each visit
Time frame: week 0, week 24, week 48
The Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)
Anti-drug antibodies (ADA) responses at baseline and post baseline.
Time frame: Pre-treatment until end of 48-week end of treatment
Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Percent change from baseline at Week 48 in blood eosinophil levels
Time frame: From randomization through Study Week 48
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups
Time frame: From randomization through Study Week 48.
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)
Time frame: From randomization through Study Week 48
Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.
Time frame: From randomization through Study Week 48
695 participants were randomized to receive treatment in study D3250C00036 (MIRACLE) with Benralizumab or placebo. All the 695 randomized participants received treatment with study drug.
| Milestone | Benralizumab 30 mg | Placebo |
|---|---|---|
| Started | 348 | 347 |
| Dosed | 348 | 347 |
| Completed | 331 | 321 |
| Not completed | 17 | 26 |
| Withdrew: Withdrawal by subject | 11 | 22 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: V18 skipped due to logistics reason | 1 | 0 |
| Withdrew: Pi decided to discontinue the study due to the lack of crc resources | 0 | 2 |
| Withdrew: Fail to meet randomization criteria | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups
| events/patient-year | Benralizumab 30 mg | Placebo |
|---|---|---|
| Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL | 0.49 (0.33 to 0.72) | 1.88 (1.35 to 2.61) |
Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)
| Liter | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | 0.333 ± 0.4499 | 0.103 ± 0.4841 |
Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.
| Scores on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -1.07 ± 1.126 | -0.80 ± 1.129 |
Change from baseline at week 48 in total rescue medication use (number of puffs/day)
| Puffs/day | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -0.85 ± 1.865 | -0.89 ± 2.213 |
Change from baseline at week 48 in morning PEF
| L/min | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | 54.194 ± 86.3963 | 12.995 ± 68.7947 |
Change from baseline at week 48 in evening PEF
| L/min | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | 45.661 ± 85.4642 | 7.989 ± 68.0632 |
Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication
| Proportion of nights | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -0.15 ± 0.220 | -0.15 ± 0.260 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.
| Scores on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -1.22 ± 0.901 | -0.79 ± 0.962 |
Time to first asthma exacerbation over 48-week treatment period
| Days | Benralizumab 30 mg | Placebo |
|---|---|---|
| Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | NA (NA to NA) | 227 (146 to NA) |
Number and percentage of patients with at least one exacerbation over 48-week treatment period
| Participants | Benralizumab 30 mg | Placebo |
|---|---|---|
| Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | 55 | 125 |
The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.
| Scores on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -23.24 ± 20.509 | -14.75 ± 21.838 |
Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period
| events/patient-year | Benralizumab 30 mg | Placebo |
|---|---|---|
| Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | 0.06 (0.04 to 0.11) | 0.14 (0.09 to 0.20) |
Asthma specific health care resource utilization over 48-week treatment period.
| Participants | Benralizumab 30 mg | Placebo |
|---|---|---|
| Hospitalisations | 6 | 21 |
| Emergency Department Visits | 11 | 12 |
| Unscheduled Outpatient Visits | 53 | 99 |
| Home Visits | 1 | 2 |
| Telephone Calls | 35 | 71 |
| Ambulance Transports | 2 | 2 |
| Advanced Pulmonary Function Test | 4 | 8 |
PK trough concentrations at each visit
| ng/mL | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 0 | 0 ± 0 | — |
| Week 24 | 137.914 ± 432.419 | — |
| Week 48 | 123.476 ± 395.951 | — |
Anti-drug antibodies (ADA) responses at baseline and post baseline.
| Participants | Benralizumab 30 mg | Placebo |
|---|---|---|
| ADA positive at any time, including baseline and/or post-baseline (ADA prevalence) | 58 | 6 |
| Treatment-emergent ADA positive, including treatment-induced and treatment-boosted ADA positive | 58 | 2 |
| Treatment-induced ADA positive | 56 | 2 |
| Treatment-boosted ADA positive | 2 | 0 |
| ADA positive at both baseline and at least one post-baseline assessment | 2 | 2 |
| ADA positive at baseline only | 0 | 2 |
| ADA persistently positive | 40 | 1 |
| ADA transiently positive | 16 | 1 |
| ADA positive with maximum titre > median of maximum titres | 25 | 2 |
| ADA positive with maximum titre <= median of maximum titres | 33 | 4 |
| nAb prevalence (nAb positive at any time, including baseline and/or post-baseline) | 55 | 1 |
| nAb incidence | 55 | 1 |
Percent change from baseline at Week 48 in blood eosinophil levels
| Percent change | Benralizumab 30 mg | Placebo |
|---|---|---|
| Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL | -80.6 ± 34.65 | 42.3 ± 380.86 |
Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups
| events/patient-year | Benralizumab 30 mg | Placebo |
|---|---|---|
| Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL | 0.72 (0.49 to 1.06) | 0.87 (0.61 to 1.24) |
Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)
| Liter | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL | 0.178 ± 0.4068 | 0.045 ± 0.3626 |
Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.
| Scores on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL | -0.97 ± 1.260 | -0.75 ± 1.105 |
Collected over From initial dose of the study treatment to the end of study, i.e., up to 56 weeks of follow-up.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30 mg | 0/348 (0%) | 44/348 (12.6%) | 194/348 (55.7%) |
| Placebo | 0/347 (0%) | 63/347 (18.2%) | 194/347 (55.9%) |
| Event | Benralizumab 30 mg | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 12/348 | 33/347 |
| PneumoniaInfections and infestations | 3/348 | 6/347 |
| Pneumonia bacterialInfections and infestations | 3/348 | 3/347 |
| CataractEye disorders | 1/348 | 3/347 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 3/348 | 1/347 |
| Lower respiratory tract infectionInfections and infestations | 0/348 | 2/347 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/348 | 2/347 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/348 | 2/347 |
| Chronic sinusitisInfections and infestations | 2/348 | 0/347 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 2/348 | 0/347 |
| Event | Benralizumab 30 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 120/348 | 120/347 |
| NasopharyngitisInfections and infestations | 28/348 | 33/347 |
| BronchitisInfections and infestations | 11/348 | 27/347 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 22/348 | 15/347 |
| PyrexiaGeneral disorders | 18/348 | 9/347 |
| PneumoniaInfections and infestations | 9/348 | 16/347 |
| PharyngitisInfections and infestations | 13/348 | 13/347 |
| HypertensionVascular disorders | 7/348 | 13/347 |
| RhinitisInfections and infestations | 13/348 | 6/347 |
| Urinary tract infectionInfections and infestations | 9/348 | 12/347 |
Full analysis set, all participants who were randomized and received at least one investigational product (IP), Benralizumab or Placebo.
| Age, Continuous(years) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Mean | 51.1 ± 11.56 | 51.0 ± 12.56 | 51.1 ± 12.06 |
| Age, Customized(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| >=12 - <18 years | 1 | 0 | 1 |
| >=18 - <65 years | 299 | 295 | 594 |
| >=65 - <=75 | 48 | 52 | 100 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Female | 221 | 207 | 428 |
| Male | 127 | 140 | 267 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Non-Hispanic or Latino | 348 | 347 | 695 |
| Asian | 348 | 347 | 695 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2017 to primary completion in Jan 2023, 64 months.
Results were first posted in Apr 2024, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 64 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab